Carlo Pulitano

Dr. Carlo Pulitano

Transplantation and HPB Surgery, Royal Prince Alfred Hospital, Sydney, Australia

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2009 in Annals of Surgery
Verified
Journal Article
Closed access
MJMechteld C de Jong
Mechteld C de Jong
Carlo PulitanoCarlo Pulitano
Carlo Pulitano
DRDario Ribero
Dario Ribero
JSJennifer Strub
Jennifer Strub
GMGilles Mentha
Gilles Mentha
TPTimothy M. Pawlik
Timothy M. Pawlik
To investigate rates and patterns of recurrence in patients following curative intent surgery for colorectal liver metastasis. Outcomes following surgical management of colorectal liver metastasis have largely focused on overall survival. Contemporary data on rates and patterns of recurrence following surgery for colorectal liver metastasis are limited. One thousand six hundred sixty-nine patients treated with surgery (resection +/- radiofrequency ablation [RFA]) for colorectal liver metastasis between 1982 and 2008 were identified from an international multi-institutional database. Clinicopathologic data, recurrence patterns, and recurrence-free survival (RFS) were analyzed. At the time of the initial liver-directed surgery, surgical treatment was resection only (90.2%), resection plus RFA (8.0%), or RFA alone (1.8%). While 5-year overall survival was 47.3%, 947 (56.7%) patients recurred with a median RFS time of 16.3 months. First recurrence site was intrahepatic only (43.2%), extrahepatic only (35.8%), intra- and extrahepatic (21.0%). There was no difference in RFS based on site of recurrence (intrahepatic: 16.9 months; extrahepatic: 16.6 months; intra- and extrahepatic: 16.2 month; P > 0.05). Receipt of adjuvant chemotherapy was associated with overall recurrence risk (hazard ratio [HR] = 0.56), while history of RFA (HR = 2.39, P = 0.001) and R1 margin status (HR = 1.36) were predictive of intrahepatic recurrence. Pattern of recurrence and RFS remained similar following repeat surgery for recurrent disease. While 5-year survival following surgery for colorectal liver metastasis approaches 50%, over one-half of patients develop recurrence within 2 years. The pattern of failure is distributed relatively equally among intrahepatic, extrahepatic, and intra- plus extrahepatic sites. Patients undergoing repeat surgery for recurrent metastasis have similar patterns of recurrence and RFS time.

10 August 2011 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MJMechteld C de Jong
Mechteld C de Jong
HNHari Nathan
Hari Nathan
GSGeorgios C. Sotiropoulos
Georgios C. Sotiropoulos
APAndreas Paul
Andreas Paul
SASorin Alexandrescu
Sorin Alexandrescu
TPTimothy M. Pawlik
Timothy M. Pawlik
Purpose: To identify factors associated with outcome after surgical management of intrahepatic cholangiocarcinoma (ICC) and examine the impact of lymph node (LN) assessment on survival.Patients and Methods: From an international multi-institutional database, 449 patients who underwent surgery for ICC between 1973 and 2010 were identified. Clinical and pathologic data were evaluated using uni- and multivariate analyses.Results: Median tumor size was 6.5 cm. Most patients had a solitary tumor (73%) and no vascular invasion (69%). Median survival was 27 months, and 5-year survival was 31%. Factors associated with adverse prognosis included positive margin status (hazard ratio [HR], 2.20; P < .001), multiple lesions (HR, 1.80; P = .001), and vascular invasion (HR, 1.59; P = .015). Tumor size was not a prognostic factor (HR, 1.03; P = .23). Patients were stratified using the American Joint Committee on Cancer/International Union Against Cancer T1, T2a, and T2b categories (seventh edition) in a discrete step-wise fashion (P < .001). Lymphadenectomy was performed in 248 patients (55%); 74 of these (30%) had LN metastasis. LN metastasis was associated with worse outcome (median survival: N0, 30 months v N1, 24 months; P = .03). Although patients with no LN metastasis were able to be stratified by tumor number and vascular invasion (N0; P < .001), among patients with N1 disease, multiple tumors and vascular invasion, either alone or together, failed to discriminate patients into discrete prognostic groups (P = .34).Conclusion: Although tumor size provides no prognostic information, tumor number, vascular invasion, and LN metastasis were associated with survival. N1 status adversely affected overall survival and also influenced the relative effect of tumor number and vascular invasion on prognosis. Lymphadenectomy should be strongly considered for ICC, because up to 30% of patients will have LN metastasis.

29 June 2010 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
SMSkye C. Mayo
Skye C. Mayo
MJMechteld C de Jong
Mechteld C de Jong
Carlo PulitanoCarlo Pulitano
Carlo Pulitano
BCBrian M. Clary
Brian M. Clary
SRSrinevas K. Reddy
Srinevas K. Reddy
Tim PawlikTim Pawlik
Tim Pawlik

1 May 2014 in JAMA Surgery
Verified
Journal Article
Open access
PDF file
OHOmar Hyder
Omar Hyder
HMHugo Pinto Marques
Hugo Pinto Marques
Carlo PulitanoCarlo Pulitano
Carlo Pulitano
JMJ. Wallis Marsh
J. Wallis Marsh
SASorin Alexandrescu
Sorin Alexandrescu
Tim PawlikTim Pawlik
Tim Pawlik
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver malignant tumor after hepatocellular carcinoma (HCC). It represents 10% to 20% of all primary liver malignant tumors, with an estimated 3100 new cases of ICC occurring every year in the United States.1 A relatively uncommon disease with a poor prognosis for survival, the incidence of ICC has been increasing during the last 3 decades.2,3 Surgical resection is the mainstay of curative intent treatment for ICC and is associated with improved survival in selected patients.2,3 We previously published data on a large, multi-institutional, multinational cohort of patients and noted that 5-year survival after surgical resection was 30% to 35%.3

1 June 2013 in Surgery
Verified
Journal Article
Closed access
OHOmar Hyder
Omar Hyder
IHIoannis Hatzaras
Ioannis Hatzaras
GSGeorgios C. Sotiropoulos
Georgios C. Sotiropoulos
APAndreas Paul
Andreas Paul
SASorin Alexandrescu
Sorin Alexandrescu
Tim PawlikTim Pawlik
Tim Pawlik

10 June 2015 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
Gaya SpolveratoGaya Spolverato
Gaya Spolverato
YKYuhree Kim
Yuhree Kim
SASorin Alexandrescu
Sorin Alexandrescu
HMHugo Pinto Marques
Hugo Pinto Marques
JLJorge Lamelas
Jorge Lamelas
Tim PawlikTim Pawlik
Tim Pawlik